Diversified Trust Co Sells 3,664 Shares of Colgate-Palmolive Company (NYSE:CL)

Diversified Trust Co trimmed its stake in shares of Colgate-Palmolive Company (NYSE:CL - Free Report) by 4.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 79,696 shares of the company's stock after selling 3,664 shares during the quarter. Diversified Trust Co's holdings in Colgate-Palmolive were worth $7,468,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Brighton Jones LLC raised its stake in Colgate-Palmolive by 4.4% during the fourth quarter. Brighton Jones LLC now owns 10,578 shares of the company's stock worth $962,000 after acquiring an additional 450 shares in the last quarter. Bernard Wealth Management Corp. acquired a new stake in shares of Colgate-Palmolive in the 4th quarter valued at $36,000. Lake Street Advisors Group LLC grew its holdings in shares of Colgate-Palmolive by 4.4% in the 4th quarter. Lake Street Advisors Group LLC now owns 5,216 shares of the company's stock worth $474,000 after purchasing an additional 221 shares during the last quarter. Bryn Mawr Capital Management LLC increased its position in shares of Colgate-Palmolive by 91.3% during the 4th quarter. Bryn Mawr Capital Management LLC now owns 20,433 shares of the company's stock worth $1,858,000 after purchasing an additional 9,751 shares in the last quarter. Finally, Checchi Capital Advisers LLC lifted its holdings in Colgate-Palmolive by 2.1% during the 4th quarter. Checchi Capital Advisers LLC now owns 7,893 shares of the company's stock valued at $718,000 after purchasing an additional 164 shares during the last quarter. 80.41% of the stock is currently owned by institutional investors.

Colgate-Palmolive Trading Up 0.1%

Shares of CL opened at $87.85 on Friday. The stock's fifty day simple moving average is $90.99 and its 200-day simple moving average is $90.64. The firm has a market capitalization of $71.19 billion, a PE ratio of 24.82, a price-to-earnings-growth ratio of 4.66 and a beta of 0.38. Colgate-Palmolive Company has a 12-month low of $85.32 and a 12-month high of $109.30. The company has a quick ratio of 0.54, a current ratio of 0.85 and a debt-to-equity ratio of 8.96.

Colgate-Palmolive (NYSE:CL - Get Free Report) last announced its quarterly earnings data on Friday, April 25th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.86 by $0.05. Colgate-Palmolive had a return on equity of 461.04% and a net margin of 14.52%. The firm had revenue of $4.91 billion during the quarter, compared to analysts' expectations of $4.92 billion. The company's quarterly revenue was down 3.0% compared to the same quarter last year. During the same period in the previous year, the business posted $0.86 EPS. As a group, research analysts predict that Colgate-Palmolive Company will post 3.75 earnings per share for the current year.

Colgate-Palmolive declared that its Board of Directors has initiated a share repurchase plan on Thursday, March 20th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the company to purchase up to 6.8% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company's board believes its shares are undervalued.

Colgate-Palmolive Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 15th. Investors of record on Friday, July 18th will be paid a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.37%. The ex-dividend date of this dividend is Friday, July 18th. Colgate-Palmolive's dividend payout ratio (DPR) is 58.76%.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on CL shares. Piper Sandler decreased their price objective on shares of Colgate-Palmolive from $108.00 to $107.00 and set an "overweight" rating on the stock in a research note on Monday, March 31st. UBS Group boosted their target price on Colgate-Palmolive from $105.00 to $109.00 and gave the stock a "buy" rating in a report on Thursday, April 17th. Wells Fargo & Company increased their price target on Colgate-Palmolive from $83.00 to $88.00 and gave the stock an "underweight" rating in a research report on Wednesday, April 2nd. Citigroup raised their price target on Colgate-Palmolive from $103.00 to $108.00 and gave the company a "buy" rating in a report on Monday, April 28th. Finally, Barclays reduced their price objective on Colgate-Palmolive from $89.00 to $86.00 and set an "equal weight" rating on the stock in a research note on Friday, April 11th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat.com, Colgate-Palmolive has an average rating of "Hold" and an average target price of $101.69.

Colgate-Palmolive Profile

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.

Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive Company (NYSE:CL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.